Provided by Tiger Trade Technology Pte. Ltd.

Legend Biotech

21.42
-0.2300-1.06%
Pre-market: 21.490.0665+0.31%08:21 EST
Volume:1.65M
Turnover:35.68M
Market Cap:3.96B
PE:-16.44
High:22.02
Open:21.67
Low:21.39
Close:21.65
52wk High:45.30
52wk Low:21.39
Shares:184.69M
Float Shares:81.38M
Volume Ratio:0.68
T/O Rate:2.03%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.3026
EPS(LYR):-0.9681
ROE:-22.53%
ROA:-6.92%
PB:3.91
PE(LYR):-22.12

Loading ...

Legend Biotech Is Maintained at Overweight by Cantor Fitzgerald

Dow Jones
·
Yesterday

Legend Biotech Is Maintained at Overweight by Morgan Stanley

Dow Jones
·
Dec 13

Legend Biotech's Stock Weakness After Rival Treatment Update 'Overdone,' RBC Says

MT Newswires Live
·
Dec 11

Cancer Study Buoys These Small Biotechs -- Barrons.com

Dow Jones
·
Dec 10

HK Stock Movement | GENSCRIPT BIO (01548) Extends Losses by Over 11% in Afternoon Session as Affiliate Legend Biotech Drops 7% Overnight

Stock News
·
Dec 09

Legend Biotech Is Maintained at Buy by UBS

Dow Jones
·
Dec 08

UBS Adjusts Legend Biotech Price Target to $48 From $54, Maintains Buy Rating

MT Newswires Live
·
Dec 08

Legend Biotech Reports CARVYKTI® Delivers Median PFS of 50.4 Months in Multiple Myeloma Trial

Reuters
·
Dec 08

GenScript Affiliate Legend Biotech Showcases CAR-T Data at 2025 ASH Meeting

Reuters
·
Dec 07

BRIEF-Legend Biotech Highlights New Carvykti® Data In Multiple Myeloma And First-In-Human Results From Novel Car-T Platform In Non-Hodgkin Lymphoma At Ash 2025

Reuters
·
Dec 07

Legend Biotech Highlights New Carvykti® Data in Multiple Myeloma and First-in-Human Results From Novel CAR-T Platform in Non-Hodgkin Lymphoma at Ash 2025

THOMSON REUTERS
·
Dec 07

Legend Biotech Reports CARVYKTI Achieves 50.4-Month Median PFS in Multiple Myeloma Trial

Reuters
·
Dec 07

Legend Biotech Awarded 2025 FIBA Foreign Investor of the Year by Flanders Investment & Trade

GlobeNewswire
·
Nov 27

Final Victory in Court! Former Legend Biotech Executive: A Triumph for Justice

Deep News
·
Nov 20

Why Genscript Biotech (SEHK:1548) Is Up 8.0% After Legend Biotech’s CARVYKTI Drives Smaller Q3 Loss

Simply Wall St.
·
Nov 15

Legend Biotech Celebrates Official Opening of New State-of-the-Art Cell Therapy Research and Development Facility in Philadelphia

GlobeNewswire
·
Nov 14

Morgan Stanley Reaffirms Their Buy Rating on Legend Biotech (LEGN)

TIPRANKS
·
Nov 13

Legend Biotech Is Maintained at Overweight by Cantor Fitzgerald

Dow Jones
·
Nov 13

Cantor Fitzgerald Sticks to Their Buy Rating for Legend Biotech (LEGN)

TIPRANKS
·
Nov 13

Legend Biotech : Barclays Cuts Target Price to $90 From $94

THOMSON REUTERS
·
Nov 13